Blood TransfusionPub Date : 2024-09-01Epub Date: 2024-07-19DOI: 10.2450/BloodTransfus.722
Alexandre Soares Ferreira Junior, Morgana Pinheiro Maux Lessa, Kate Sanborn, Alexander Gordee, Maragatha Kuchibhatla, Matthew S Karafin, Oluwatoyosi A Onwuemene
{"title":"Bleeding recurrence risk among hospitalized patients undergoing therapeutic plasma exchange: a multi-center study.","authors":"Alexandre Soares Ferreira Junior, Morgana Pinheiro Maux Lessa, Kate Sanborn, Alexander Gordee, Maragatha Kuchibhatla, Matthew S Karafin, Oluwatoyosi A Onwuemene","doi":"10.2450/BloodTransfus.722","DOIUrl":"10.2450/BloodTransfus.722","url":null,"abstract":"<p><strong>Background: </strong>In hospitalized patients undergoing therapeutic plasma exchange (TPE), it is not known how TPE-associated bleeding risk is impacted by a prior bleeding episode. Therefore, to assess the prevalence and predictors of bleeding recurrence, we analyzed data from the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).</p><p><strong>Materials and methods: </strong>Using a retrospective cross-sectional analysis of REDS-III public use files, we identified hospitalized adults who had a major bleeding episode prior to their first TPE procedure. Patients were classified into two cohorts based on bleeding recurrence (no-recurrence vs recurrence). After identifying potential predictors, we used multiple imputation by chained equations to impute variables with <30% missing data. Variable selection was optimized using a 10-fold cross validated least absolute shrinkage and selection operator. Final predictors were identified by fitting a logistic regression model.</p><p><strong>Results: </strong>In 310 patients with major bleeding prior to TPE initiation, bleeding recurred in 121 (39.0%). We identified the following seven unique predictors: 1) >10 TPE procedures (OR 2.23); 2) intensive care unit stay (OR 1.35); 3) thrombocytopenia (OR 1.26); 4) surgery (OR 1.22); 5) hepatic disease (OR 1.21); 6) 6-10 TPE procedures (OR 1.04); and 7) Asian race (OR 1.01). We also identified the following five interactions: 1) surgery and therapeutic anticoagulation (OR 1.50); 2) 6-10 TPE procedures and therapeutic anticoagulation (OR 1.05); 3) 6-10 TPE procedures and antiplatelets (OR 1.02); 4) >10 TPE procedures and antiplatelets (OR 1.00); and 5) albumin-only TPE and antiplatelets (OR 0.53). When assessed for adjusted performance, the prediction model had a C-statistic of 0.617 (95% CI 0.613-0.619) and Brier Score of 0.342 (95% CI 0.340-0.347).</p><p><strong>Discussion: </strong>In this study assessing predictors of bleeding recurrence among hospitalized patients undergoing TPE, we identified seven variables and five interactions. These findings should be validated in future studies.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"420-428"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-09-01Epub Date: 2024-01-09DOI: 10.2450/BloodTransfus.600
Stavros Tsalas, Andreas G Tsantes, Eleni Petrou, Sofia Mellou, Rozeta Sokou, Electra Loukopoulou, Anastasios G Kriebardis, Sotirios P Fortis, Dimitrios V Papadopoulos, Aristeidis G Vaiopoulos, Styliani Kokoris, Argirios E Tsantes
{"title":"The effects of pathogen reduction technology on apheresis platelet concentrates stored in PAS.","authors":"Stavros Tsalas, Andreas G Tsantes, Eleni Petrou, Sofia Mellou, Rozeta Sokou, Electra Loukopoulou, Anastasios G Kriebardis, Sotirios P Fortis, Dimitrios V Papadopoulos, Aristeidis G Vaiopoulos, Styliani Kokoris, Argirios E Tsantes","doi":"10.2450/BloodTransfus.600","DOIUrl":"10.2450/BloodTransfus.600","url":null,"abstract":"<p><strong>Background: </strong>The impact of pathogen reduction technology (PRT) such as Mirasol, and the effect of platelet additive solutions (PAS) on the activity and hemostatic profile of transfused apheresis platelets remain largely unknown. The aim of this study was to assess the in vitro hemostatic and metabolic profile of Mirasol treated platelets in PAS during a 7-day storage period.</p><p><strong>Material and methods: </strong>Ten split bags containing apheresis platelets stored in PAS were split into two groups; control platelets (No.=10 units) and PRT-treated platelets (No.=10 units). In vitro evaluation of the platelet components was performed on the 1<sup>st</sup>, 3<sup>rd</sup>, 5<sup>th</sup>, and 7<sup>th</sup> days of the storage period. Several metabolic parameters including pH, glucose, and lactate levels were evaluated, while assessment of their hemostatic capacity was performed using light transmission aggregometry (LTA) and viscoelastic studies such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG). Last, Annexin V levels were measured though flow cytometry for evaluation of platelet activation.</p><p><strong>Results: </strong>Clot strength, as reflected by the maximum clot firmness (MCF) and the maximum amplitude (MA) parameters of the viscoelastic studies was significantly decreased in the PRT-treated platelets compared to the control platelets (p<0.05). Clot strength based on MCF and MA values was also found to be decreasing over storage time in PRT-treated platelets (p<0.001), while this was not evident in control platelets. Moreover, the comparison between pH, glucose, and lactate levels were indicative of increased metabolic activity in PRT-treated platelets compared to control platelets (p<0.001). Last, Annexin-V was significantly higher in PRT-treated platelets compared to control platelets on the 7<sup>th</sup> day of the storage period (p<0.001).</p><p><strong>Discussion: </strong>The results of this study indicate that increased PSL induced by PRT treatment leads to a decreased in vitro platelet hemostatic efficacy and increased metabolic activity. However, the clinical impact of these alterations needs further investigation.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"405-414"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-09-01Epub Date: 2024-04-23DOI: 10.2450/BloodTransfus.741
Cecilia Pardi, Åsa Hellberg, Pauline Isakson
{"title":"Single-exon fetal RHD genotyping: a 31-month follow up in the obstetric population of Western Sweden.","authors":"Cecilia Pardi, Åsa Hellberg, Pauline Isakson","doi":"10.2450/BloodTransfus.741","DOIUrl":"10.2450/BloodTransfus.741","url":null,"abstract":"<p><strong>Background: </strong>The Rh blood group system is highly complex, polymorphic, and immunogenic. The presence of RHD gene variants in RhD negative pregnant women is a challenge in fetal RHD genotyping as it may influence the antenatal management of anti-D prophylaxis. The aim of this study was to determine the efficiency of a non-invasive single-exon approach in the obstetric population of Western Sweden in a 31-month follow up. The frequency and type of maternal RHD variants were explored and the relation to the ethnicity was elucidated. Discrepant results between fetal RHD genotyping and serological blood group typing of newborns were investigated and clarified.</p><p><strong>Materials and methods: </strong>RHD exon 4 was analysed with quantitative real-time PCR technique in a total of 6,948 blood samples from RhD negative women in early pregnancy. All cases with suspected maternal RHD gene and discrepant results observed in newborn samples, were further investigated using both serological and molecular technologies.</p><p><strong>Results: </strong>A total of 43 samples (0.6%) had inconclusive fetal genotyping result due the presence of a maternal RHD gene. These findings were in most cases (>66%) observed in pregnant women of non-European ancestry. Additionally, two novel RHD alleles were found. Seven discrepant results between fetal RHD genotype and serological RhD type of the newborns, were shown to be related to D antigen variants in newborns. Assay sensitivity was 99.95%, specificity 100%, and accuracy 99.97%.</p><p><strong>Discussion: </strong>The single-exon approach for fetal RHD screening early in pregnancy is an appropriate choice in the population of Western Sweden, with a very low frequency of inconclusive results caused by the presence of maternal RHD gene variants. Due to the high sensitivity, specificity, and accuracy of the test, serological typing of neonates born to RhD negative women has no longer been performed at our laboratory since June 2023.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"387-394"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-09-01Epub Date: 2024-05-16DOI: 10.2450/BloodTransfus.778
Dragoslav Domanović, Antoine Lewin, Peter O'Leary, Tiziana Janner-Jametti, Soraya Amar El Dusouqui, Ana Paula Sousa, Hans Zaaijer, Barnaby Roberts, Daisy Bougard, Daniele Prati, Jonas Nordberg, Christian Erikstrup, Mart Janssen, Ryanne Lieshout-Krikke, Knut Gubbe, Niamh O'Flaherty, Genevieve Mathy, Andrée-Marie Chantillon, Riikka Lehtisalo, Øfsteng H Sørensen, Pierre Tiberghien, Stephen Thomas
{"title":"Assessing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease: a European perspective.","authors":"Dragoslav Domanović, Antoine Lewin, Peter O'Leary, Tiziana Janner-Jametti, Soraya Amar El Dusouqui, Ana Paula Sousa, Hans Zaaijer, Barnaby Roberts, Daisy Bougard, Daniele Prati, Jonas Nordberg, Christian Erikstrup, Mart Janssen, Ryanne Lieshout-Krikke, Knut Gubbe, Niamh O'Flaherty, Genevieve Mathy, Andrée-Marie Chantillon, Riikka Lehtisalo, Øfsteng H Sørensen, Pierre Tiberghien, Stephen Thomas","doi":"10.2450/BloodTransfus.778","DOIUrl":"10.2450/BloodTransfus.778","url":null,"abstract":"<p><p>Several countries have recently reassessed the international risk of variant Creutzfeldt-Jakob disease (vCJD) transmission through transfusion of blood and blood components (red blood cells, platelets and plasma) and relaxed donor deferrals based on geographic and transfusion exposure in countries formerly considered to be high risk, such as the UK. In this regard, the European Blood Alliance organised a consensus meeting of experts and involved professionals to discuss current knowledge, epidemiological data, prevention and various methods for assessing the risk of transfusion-transmitted vCJD, as well as to develop an appropriate position on possible approaches to address these challenges in Europe. Participants reached a consensus that the current risk of transfusion-transmitted vCJD associated with blood donors who either travelled to or received transfusions in the UK during the vCJD outbreak is minimal. In addressing such risks, it would be pragmatic that assessments and guidelines are developed by European expert bodies, rather than individual assessments by Member States. Regardless of the approach used, European or national, a qualitative risk assessment based on a review and analysis of available data, considering all the uncertainties and experiences of other countries, would provide crucial information to reassess blood donation strategies regarding the transfusion-associated vCJD risk.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"415-419"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"DENV outbreak in Italy: the impact on the National Transfusion Network.","authors":"Ilaria Pati, Giulio Pisani, Flavia Riccardo, Giulietta Venturi, Vincenzo De Angelis","doi":"10.2450/BloodTransfus.696","DOIUrl":"10.2450/BloodTransfus.696","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"365-366"},"PeriodicalIF":2.4,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-07-27DOI: 10.2450/BloodTransfus.566
Valeria Cortesi, Giacomo Cavallaro, Genny Raffaeli, Stefano Ghirardello, Fabio Mosca, Thomas R L Klei, Suzanne Fustolo-Gunnink, Simon Stanworth, Helen V New, Emöke Deschmann, Enrico Lopriore
{"title":"Why might cord blood be a better source of platelets for transfusion to neonates?","authors":"Valeria Cortesi, Giacomo Cavallaro, Genny Raffaeli, Stefano Ghirardello, Fabio Mosca, Thomas R L Klei, Suzanne Fustolo-Gunnink, Simon Stanworth, Helen V New, Emöke Deschmann, Enrico Lopriore","doi":"10.2450/BloodTransfus.566","DOIUrl":"10.2450/BloodTransfus.566","url":null,"abstract":"<p><p>Thrombocytopenia (defined as a platelet count <150×10<sup>9</sup>/L) is a common condition in preterm neonates and may occur in 18-35% of all infants admitted to the Neonatal Intensive Care Unit (NICU). Neonatal platelet functionality in terms of reactivity is often described as reduced compared to adults, even in healthy, term neonates. However, this platelet \"hyporeactivity\" does not correspond to a global functional impairment of the normal delicately balanced neonatal hemostatic system. The extent to which neonatal thrombocytopenia and platelet hyporeactivity contribute to the bleeding risk in preterm neonates remains unknown. Prophylactic platelet transfusions are often administered to them to reduce the risk of bleeding. However, recent literature indicates that adopting a higher platelet transfusion threshold than a lower one results in significantly higher death rates or major bleeding and can be harmful. Although the mechanism by which this occurs is not entirely clear, a mismatch between adult transfused platelets and the neonatal hemostatic system, as well as volume overload, are speculated to be potentially involved. Therefore, future research should consider novel transfusion products that may be more suitable for premature neonates. Blood products derived from umbilical cord blood (UCB) are promising, as they might perfectly match neonatal blood features. Here, we discuss the current knowledge about UCB-derived products, focusing on UCB-derived platelet concentrates and their potential for future clinical application. We will discuss how they may overcome the potential risks of transfusing adult-derived platelets to premature infants while maintaining efficacy.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"292-302"},"PeriodicalIF":2.4,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-07-21DOI: 10.2450/BloodTransfus.601
Anna Lecchi, Marco Capecchi, Lidia Padovan, Andrea Artoni, Nobuo Arai, Sho Shinohara, Silvia La Marca, Flora Peyvandi
{"title":"Evaluation of an automated platelet aggregation method for detection of congenital or acquired platelet function defects.","authors":"Anna Lecchi, Marco Capecchi, Lidia Padovan, Andrea Artoni, Nobuo Arai, Sho Shinohara, Silvia La Marca, Flora Peyvandi","doi":"10.2450/BloodTransfus.601","DOIUrl":"10.2450/BloodTransfus.601","url":null,"abstract":"<p><strong>Background: </strong>Light transmission aggregometry (LTA) is the most widely used laboratory method for an initial screening of patients with a suspected platelet function defect (PFD), and its use has also been proposed for assessing the efficacy of antiplatelet treatment (APT). An automated LTA method has been developed by Sysmex (Kobe, Japan) on a routine coagulation analyzer (CS-2400), together with a new research parameter called PAL (platelet aggregation level) to evaluate patients on APT.</p><p><strong>Materials and methods: </strong>We evaluated the performance of CS-2400 compared to a stand-alone lumi-dual-aggregometer device in the diagnosis of PFD and in assessing the efficacy of APT. For these purposes, the study population was represented by a cohort of 23 patients with a previous diagnosis of PFD and a cohort of 28 patients on APT.</p><p><strong>Results: </strong>Compared to healthy volunteers, patients with PFD showed a statistically significant reduction (p<0.05) in the maximal %light transmission, irrespective of the agonist used, both with the CS-2400 and the lumi-dual-aggregometer. As regards PFD patients, CS-2400 was effective in identifying the more severe defects, with a good sensibility and specificity, but less effective in identifying milder forms of PFD, such as platelet secretion defects. Patients on APT showed a statistically significant (p=0.001) reduced median %light transmission and PAL scores compared to healthy controls.</p><p><strong>Discussion: </strong>Thanks to this LTA technology, CS-2400, a routine coagulation analyzer widely available in routine laboratories, could prove useful for initial assessment of patients with a suspected PFD. Moreover, the PAL scores were a fairly accurate reflection of the platelet response to APT.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"350-359"},"PeriodicalIF":2.4,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-07-19DOI: 10.2450/BloodTransfus.689
Dong Woo Shin, Yun Ji Hong, Kyoung Un Park
{"title":"Establishment of a case registry that collaborates with a reference laboratory for blood group immunogenetics in Korea.","authors":"Dong Woo Shin, Yun Ji Hong, Kyoung Un Park","doi":"10.2450/BloodTransfus.689","DOIUrl":"10.2450/BloodTransfus.689","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"363-364"},"PeriodicalIF":2.4,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-07-15DOI: 10.2450/BloodTransfus.753
Willy Albert Flegel
{"title":"Patients with red cell antibodies: registries improve patient care by increasing patient safety, reducing costs, and enabling health information exchange.","authors":"Willy Albert Flegel","doi":"10.2450/BloodTransfus.753","DOIUrl":"10.2450/BloodTransfus.753","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"279-282"},"PeriodicalIF":2.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood TransfusionPub Date : 2024-07-15DOI: 10.2450/BloodTransfus.718
Jin Hyen Baek, Hye Kyung H Shin, Fei Xu, Xiaoyuan Zhang, Matthew C Williams, Yamei Gao, Jaroslav G Vostal, Paul W Buehler, Carlos Villa, Felice D'Agnillo
{"title":"Ultraviolet light and riboflavin accelerates red blood cell dysfunction in vitro and in a guinea pig transfusion model.","authors":"Jin Hyen Baek, Hye Kyung H Shin, Fei Xu, Xiaoyuan Zhang, Matthew C Williams, Yamei Gao, Jaroslav G Vostal, Paul W Buehler, Carlos Villa, Felice D'Agnillo","doi":"10.2450/BloodTransfus.718","DOIUrl":"10.2450/BloodTransfus.718","url":null,"abstract":"<p><strong>Background: </strong>Quality assessment of modified or processed red blood cell (RBC) components, such as pathogen-reduced RBCs, using only in vitro testing may not always be predictive of in vivo performance. Mouse or rat in vivo models are limited by a lack of applicability to certain aspects of human RBC biology. Here, we used a guinea pig model to study the effects of riboflavin combined with UV light on the integrity of RBCs in vitro and following transfusion in vivo.</p><p><strong>Materials and methods: </strong>Guinea pig RBCs were collected from whole blood (WB) treated with varying UV doses (10, 20, 40 or 80 J/mL) in the presence of riboflavin (UVR-RBCs). In vitro tests for UVR-RBCs included hemolysis, osmotic fragility, and cellular morphology by scanning electron microscopy. Guinea pigs transfused with one-day post-treatment UVR-RBCs were evaluated for plasma hemoglobin (Hb), non-transferrin bound iron (NTBI), total iron and Perls-detectable hemosiderin deposition in the spleen and kidney, and renal uptake of Hb.</p><p><strong>Results: </strong>Acute RBC injury was dose dependently accelerated after treatment with UV light in the presence of riboflavin. Aberrant RBC morphology was evident at 20, 40, and 80 J/mL, and membrane lysis with Hb release was prominent at 80 J/mL. Guinea pigs transfused with 40 and 80 J/mL UVR-RBCs showed increased plasma Hb levels, and plasma NTBI was elevated in all UVR-RBC groups (10-80 J/mL). Total iron levels and Perls-hemosiderin staining in spleen and kidney as well as Hb uptake in renal proximal tubules were increased 8 hours post-transfusion with 40 and 80 J/mL UVR-RBCs.</p><p><strong>Discussion: </strong>UVR-RBCs administered to guinea pigs increased markers of intravascular and extravascular hemolysis in a UV dose-dependent manner. This model may allow for the discrimination of RBC injury during testing of extensively processed RBCs intended for transfusion.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"316-327"},"PeriodicalIF":2.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}